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1. Introduction 
Prion diseases or transmissible spongiform encephalopathies (TSEs) are rare, fatal and 
incurable neurodegenerative disorders of humans and animals (Prusiner, 1998). 
In humans, prion diseases occur with unique aetiology as sporadic, genetic or infectious 
disorders. Sporadic cases of prion diseases, which account for the majority of casualties (up 
to 85% of all cases), are of unknown origin; the genetic forms are less frequent (up to 15%), 
while the infectious cases are extremely rare with an incidence of less than 1% (Prusiner, 
2001). Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) syndrome, 
Fatal Familial Insomnia (FFI) are examples of human prion diseases. In animals the disease 
is mostly infectious and the mode of transmission is horizontal. Prion diseases include 
scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, and chronic 
wasting disease of deer, elk, and moose (Williams, 2005). 
The agents responsible for prion diseases are infectious proteins named prions. The term 
‘prion’ was coined when Stanley B. Prusiner introduced the concept of proteinaceous 
infectious particles (Prusiner, 1982). Since the introduction of this once heretical notion, 
mounting evidence has strengthened its validity. 
In the next sections of this chapter we present and discuss the peculiar complexity of the 
molecular pathogenesis of prion diseases in humans and animals. 
2. Prion protein and prions 
2.1 The prion protein 
The prion protein (PrP) is one of the most and best-studied models for misfolding diseases. 
The cellular form of PrP (PrPC) is a glysosyl-phosphatidylinositol (GPI) anchored 
polypeptide present on the outer leaflet of the cellular membrane of most cell types in 
mammals. In humans, the PRNP gene, located in the short arm of chromosome 20 (Liao et 
al., 1986), features two exons. The second exon contains the entire open reading frame 
(ORF), which encodes for the protein. The PrPC is composed of 253 amino acids in humans, 
including 22 amino acids of endoplasmic reticulum signal sequence at the N-terminus and 
23 amino acids as GPI anchoring signal at the C-terminus (Stahl et al., 1990). The N-terminal 
region of PrPC encompasses five characteristic amino acid octarepeats that coordinate 
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copper and, to a lesser extent, other metal ions. The mature 208-residues protein possesses a 
single disulphide bridge between Cys179 and Cys214, and two sites for Asn-linked 
glycosylation within the carboxy-terminal region at position Asn181 and Asn197. 
The protein is the first system where a polypeptide has been shown to exist in at least two 
significantly different conformations, associated with radically different functions. 
The physiological function of PrPC has not been established with certainty yet; nevertheless 
its evolutionarily conserved sequence suggests that it might play an important role in 
neuronal development and physiology. Indeed one recent finding indicates a possible 
involvement of this protein in neuronal differentiation and polarization (Kanaani et al., 
2005). On account of additional evidence, it could also contribute to myelin formation and 
maintenance (Benvegnu et al., 2011a).  
A strategy often employed to identify protein function is the development of transgenic 
mouse lines with a disabled gene. Many lines of knockout (KO) mice have been developed 
for PrP (Weissmann and Flechsig, 2003). In these models, typically either the entire ORF of 
exon 3 of Prnp (in mice), or the ORF as well as flanking sequences are deleted (Weissmann 
and Flechsig, 2003). The Prnp KO mice (Prnp0/0) appear to develop and reproduce normally 
(Bueler et al., 1992), but their further evaluation found several abnormalities. The mice 
appear clinically asymptomatic yet they develop peripheral nerve demyelination, have 
increased susceptibility to ischemic brain injury, altered sleep and circadian rhythm, altered 
hippocampal neuropathology and physiology, including deficits in hippocampal-dependent 
spatial learning and hippocampal synaptic plasticity (Tobler et al., 1997, Nishida et al., 1999, 
Spudich et al., 2005, Criado et al., 2005). Mice with Prnp0/0 are also more susceptible to 
oxidative stress, and PrPC appears to play a neuroprotective role in cellular response to 
hypoxic-ischemic injury (Weise et al., 2006). Some Prnp0/0 mouse lines in which the deletion 
extends beyond the ORF, although developing normally, acquire ataxia and Purkinje cell 
loss later in life (Moore et al., 1999). 
Recent findings show development regional differences of the expression of PrP in mouse 
central nervous system (CNS), with specific white matter structures showing the earliest and 
highest expression of PrPC. Indeed, all these regions are part of the thalamo-limbic 
neurocircuitry, hence suggesting a potential role of PrPC in the development and 
functioning of this specific brain system (Benvegnu et al., 2010). 
Furthermore, the transcriptome during development for the CNS of mice lacking a 
functional Prnp gene has recently been compared with that of wild-type animals (Benvegnu 
et al., 2011b). To assess the influence of PrPC on gene expression profile in the mouse brain, a 
microarray analysis was undertaken using RNA isolated from the hippocampus at two 
different developmental stages: newborn (4.5-day-old) and adult (3-month-old) mice, both 
from wild-type and Prnp KO animals. Based on the comparison of these datasets, commonly 
co-regulated genes and uniquely de-regulated genes during postnatal development were 
identified. The absence of PrPC affected several biological pathways, the most representative 
ones being cell signaling, cell-cell communication and transduction processes, calcium 
homeostasis, nervous system development, and synaptic transmission and cell adhesion. 
However, there was only a moderate alteration of the gene expression profile in our animal 
models. PrPC deficiency did not lead to a dramatic alteration of gene expression profile, and 
produced moderately altered gene expression levels from young to adult animals. Hence, 
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these results further support silencing endogenous PrPC as therapeutic approach to prion 
diseases (Benvegnu et al., 2011b). 
Concerning PrPC cellular function, experiments have recently shown that PrPC regulates the 
cleavage of neuregulin-1 proteins (NRG1). Neuregulins provide key axonal signals, which 
regulate processes, including glial cells proliferation, survival and myelination. 
Interestingly, Prnp0/0 mice have recently been reported to have a late-onset demyelinating 
disease in the peripheral nervous system (PNS), but not in the CNS (Bremer et al., 2010). The 
comparison of wild-type and Prnp0/0 mice showed that the NRG1 processing is 
developmentally regulated in the PNS and influenced by PrPC in old but not in young 
animals. In addition, it has been found that neuregulin-3 processing — another neuregulin 
family member — is altered in the PNS of Prnp0/0 mice. These differences in neuregulin 
proteins processing are not paralleled in the CNS, thus suggesting a different cellular 
function for PrPC between the CNS and the PNS (Benvegnu et al., 2011a). 
2.2 Prions and the biology of the conversion mechanism 
Prion diseases are caused by changes in the conformation of the endogenous PrPC, which 
turns into an alternatively folded, disease-causing form called the prion, or PrPSc. The 
normal PrPC contains three -helixes and two short -sheet structures in its globular 
domain, whereas PrPSc contains fewer –helical and mostly -sheet structures (Prusiner, 
1998). PrPC and PrPSc possess the same primary polypeptide sequence, but different 
secondary and tertiary structures. PrPSc is produced by the conversion of existing PrPC into 
PrPSc. 
The process leading to PrPSc production from PrPC is not completely understood. It is 
believed that this occurs when PrPC comes into contact with PrPSc and is thus induced to 
take on the shape of PrPSc (Prusiner, 1998). The fact that mice devoid of PrPC are resistant to 
infection, as they are unable to replicate prions, provides strong evidence that PrPC is 
necessary for prion disease (Bueler et al., 1993). Although it is clear that PrPC is necessary for 
prion disease, it is still debated whether other proteins or molecules are involved in the 
conformational change in vivo (Telling et al., 1995, Deleault et al., 2003). The conversion of 
monomeric PrPC into insoluble, protease-resistant PrPSc is a process that seems to occur in 
structures denominated caveolae-like domains (CLDs) (Gorodinsky and Harris, 1995), and 
the resulting PrPSc subsequently traffics to other membranous compartments such as 
endosomes and lysosomes (Marijanovic et al., 2009). The membranes of CLDs seem to be 
composed of cholesterol-rich rafts and presumably provide the cellular environment for the 
formation of PrPSc. Two conversion and replication models have been proposed: (i) a 
nucleation-polymerization reaction, and (ii) a template-assisted conversion process. In the 
first model, the rate-limiting step is the formation of a critical amount of PrPSc to form a seed 
for the polymerization of PrPSc. In the template-assisted model, PrPC must first undergo 
conversion toward a transition state that presumably corresponds to a partially destabilized 
structure (Aguzzi and Calella, 2009). The structural transition could be mediated by an 
auxiliary molecule, which facilitates the conversion to a nascent prion (Telling et al., 1995, 
Deleault et al., 2003). In disease-affected brain homogenates, limited proteolysis completely 
hydrolyzes PrPC and produces a protease-resistant PrPSc molecule of about 140 amino acids, 
designated PrP27–30. In the presence of detergent, PrP27–30 polymerizes into amyloid 
(McKinley et al., 1991). Prion amyloids, or rods, formed by limited proteolysis and detergent 
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extraction, are indistinguishable from the filaments that aggregate to form PrP amyloid 
plaques in the CNS, exhibiting similar ultrastructural morphology and tinctorial 
characteristics after staining with Congo red dye (Prusiner et al., 1983). So far, little is known 
about the structure of prions. Several models have been proposed, attempting to satisfy all 
available biophysical, biochemical and immunochemical data on infectious prions (Govaerts 
et al., 2004). The discovery that recombinant PrP, expressed in Escherichia coli, is infectious to 
mice when polymerized into amyloid fibrils has opened new avenues for research in the 
prion field (Legname et al., 2004). Characterization of these synthetic prions revealed novel 
distinctiveness associated with neuropathological changes in mouse models of prion disease 
(Legname et al., 2005). The conformational changes acquired by the synthetic prions confer 
increasing stability to PrPSc, as measured by the amount of chaotropic agents necessary to 
completely unfold PrPSc. Moreover, a linear correlation is established when the measure of 
stability of any particular isolate is expressed as a function of mouse survival times to the 
disease (Legname et al., 2006). 
One of the strongest arguments for the existence of prions is the link between inherited 
prion diseases and mutations in the PRNP gene. Currently, almost 60 pathogenic mutations 
and several polymorphisms have been identified in the PRNP gene (Kovacs et al., 2002). 
They include missense point mutations, mostly located in the globular part, insertion or 
deletion mutations involving the N-terminal domain, and non-sense mutations resulting in 
the premature termination of PrP synthesis. Twelve polymorphisms are silent, while four of 
them alter the amino acid sequence. The most important one that markedly influences the 
disease is the M/V polymorphism at codon 129 (Collinge, 2001). The M/V polymorphism at 
position 129 is common; the homozygous M/M and V/V and the heterozygous M/V 
subjects account for 43%, 8% and 49%, respectively, in the Caucasian population 
(Zimmermann et al., 1999). This polymorphism is a key determinant of genetic susceptibility 
to acquired and sporadic prion diseases, the large majority of which occur in homozygous 
individuals (Collinge et al., 1991, Palmer et al., 1991, Windl et al., 1996). The PRNP 
heterozygotes appear to be protected from sporadic CJD (sCJD) compared to the PRNP 
homozygotes (Kobayashi et al., 2009, Baker et al., 1991, Hsiao et al., 1992). The M/V 
polymorphism at position 129 affects the disease phenotype when it is located on the 
mutant allele: D178N-129V causes familial CJD (fCJD), while D178N-129M is responsible for 
familial FFI. The M/V polymorphism located on the normal allele affects the age onset and 
duration of the disease. Patients carrying either M or V 129 codon have been observed in all 
inherited prion diseases. The altered conformation observed in human PrP mutants might 
lead to a different affinity for extracellular matrix components and cellular membranes and, 
consequently, to an aberrant localization of PrP in different cellular compartments, favoring 
formation of altered pathogenic topologies (Hegde et al., 1999). Independent evidence 
derived from cell culture studies, expressing some of the disease-linked mutants, showed 
that these mutations may affect folding and maturation of PrPC in the secretory pathway of 
neuronal cells (Ashok and Hegde, 2009). 
How mutations and polymorphisms can structurally modulate the diseases is not clear. In 
fact, until recently there was no evidence of a pathological point mutation causing 
substantial structural differences in PrP folding. 
To shed new light on the role of pathological point mutations on PrP structure, a high-
resolution 3D structure of the truncated recombinant human PrP containing the pathological 
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Q212P mutation has recently been determined and examined (Ilc et al., 2010). This mutation 
is responsible for a GSS syndrome characterized by mild amyloid PrP deposition in patients 
(Piccardo et al., 1998, Young et al., 1998). The high-resolution NMR structure of Q212P 
mutant revealed unique conformational features compared to the known structures of either 
human or other mammalian PrPC (Christen et al., 2009, Christen et al., 2008, Gossert et al., 
2005, Lopez Garcia et al., 2000, Riek et al., 1996). 
The most remarkable differences involved the C-terminal end of the protein and the β2–α2 
loop region. The Q212P mutant is the first known example of PrP structure where the α3 
helix between E200 and Y226 is broken into two helices. This breakage brings about 
dramatic changes in the hydrophobic interactions between the α3 helix and the β2–α2 loop 
region. In the wild-type protein, long-range interactions between Y225 and M166 define the 
position of the β2–α2 loop and thus the tertiary structure of the protein. In this protein type, 
the solvent-exposed surface of the β2–α2 loop and the α3 helix region is smaller, and Y169 is 
buried inside the hydrophobic cluster (Ilc et al., 2010). 
When these structural findings are compared with the already resolved NMR structures of 
human PrP, carrying respectively the CJD-related E200K (Zhang et al., 2000) and the 
artificial R220K mutation, the α3 helix appears well ordered up to the point mutation 
(Calzolai et al., 2000). After this mutation, the α3 helix shows increased flexibility and 
significantly less order. At the same time, the R220K mutation does not alter the 
hydrophobic interactions between the aromatic residues of the β2–α2 loop and the α3 helix.  
Special interest in prion biology is therefore focused on the epitope formed by the β2–α2 loop 
and the α3 helix, as this surface has been implicated in interactions with a hypothetical 
facilitator of prion conversion involved in the development of TSEs (Kaneko et al., 1997, 
Telling et al., 1995). Therefore, the plasticity of the loop may modulate the susceptibility to 
prion disease of a given species. While in PrPC from most mammalian species this loop is 
flexible, it is well defined in PrPC of elk (Gossert et al., 2005), bank vole (Clethrionomys 
glareolus) (Christen et al., 2008), tammar wallaby (Christen et al., 2009) and, as found out 
very recently, horse (Perez et al., 2010) and rabbit (Wen et al., 2010). Interestingly, elk and 
bank vole are highly susceptible to TSEs, whereas there have been no cases of prion diseases 
either in marsupials, horses or rabbits. The structure-function relationship suggested by 
these works may provide the molecular basis for understanding the generation of PrPSc in 
inherited prion diseases. In fact, the characterization of high-resolution structures of PrP 
pathological mutants and their comparison with the wild-type overall folding, highlights 
important regions in these proteins that could be involved in early events of PrP misfolding. 
This may also provide a molecular explanation for prion formation in the sporadic forms of 
prion disease. 
3. Molecular pathogenesis of prion diseases 
3.1 PrP
Sc 
conformers in human and animal prion disorders 
Human and animal TSEs exist as different prion strains characterized by distinct biological 
properties. A prion strain is defined using several criteria, such as incubation time and 
lesion profile after transmission, as well as by physico-chemical characteristics of 
pathological PrPSc conformers (Bruce et al., 1994, Aguzzi et al., 2008).  
www.intechopen.com
 
Miscellanea on Encephalopathies 
 
100 
Several studies demonstrated that prion strains can be distinguished based on different 
biochemical properties of PrPSc, encompassing conformation, glycoform profile, degrees of 
protease-resistance under different denaturing conditions, thus allowing a molecular strain 
typing classification of PrPSc (Wadsworth and Collinge, 2011). Treatment of PrPSc with 
proteinase K (PK) generates a large PK-resistant C-terminal core fragment termed PrP27-30 
which is considered the pathogenic and infectious core of PrPSc. Full-length PrPSc and PrP27-
30 are associated to the naturally occurring infectious agent causing prion diseases and are 
thought to be the primary cause of the histological changes in brains of subjects with prion 
diseases. 
In human and animal prion disorders, the remarkable heterogeneity of disease phenotypes 
is influenced by the combination of either PrPSc type or relevant PRNP polymorphisms 
(Gambetti et al., 2011). 
3.2 The biochemical phenotype of PrP
Sc 
in human and animal TSEs 
In human prion disorders, several different types of PrPSc have been recognized. PrPSc types 
are distinguished based on the electrophoretic migration and the glycosylation profile of 
PrP27-30. This is composed of a major triplet of bands which represent the differently 
glycosylated isoforms of PrPSc.  
Additional minor C-terminally truncated fragments (CTFs) resistant to proteases have been 
reported and they contribute to define the biochemical strains of PrPSc. The combination of 
PrP27-30 and CTFs is representative of specific patterns and correlates to distinct disease 
phenotypes (Zou et al., 2003, Zanusso et al., 2004). 
In sCJD, three distinct PrPSc types have been described: type 1, type 2A and type U (Fig. 1A). 
Type 1 and type 2 PrPSc are distinguished based on the different electrophoretic mobility of the 
unglycosylated form of approximately 21kDa in type 1, and 19kDa in type 2, respectively 
(Parchi et al., 1999, Gambetti et al., 2003). In contrast, type U PrPSc shares apparent gel mobility 
with type 1, though it lacks the diglycosylated isoforms (Zanusso et al., 2007). 
In variant CJD (vCJD), an unglycosylated band migrating at 19kDa and a highly glycosylated-
dominant profile characterize PrPSc; wheresas type 2A PrPSc in sCJD is distinguished by the 
highly glycosylated-dominant profile. Accordingly, the current nomenclature defines type 2A-
PrPSc associated to sCJD, and type 2B-PrPSc associated to vCJD, thus identifying BSE agent in 
humans (Collinge et al. 1996). In familial forms of CJD (E200K-129V) and FFI forms, a type 2B-
like pattern is observed (Fig. 1A). The exception to the conventional definition of PrPSc typing 
is observed in GSS mutations. In GSS, PrP27-30 is absent and pathological PrP is composed of 
intermediate fragments (IFs) of ~11kDa and ~8kDa spanning residues ~90-150 and ~60-150 
(Tagliavini et al., 1991, Tagliavini et al., 1994, Piccardo et al., 1998). According to their 
sequence, these IFs lack PrP post-translational modifications, including GPI-anchor. 
However, in GSS P102L mutation, a hybrid phenotype of PrPSc is observed. In P102L, PrPSc 
is characterized by the presence of the 8kDa intermediate fragment (PrP8), as in other GSS, 
but also of PrP27-30 (Parchi et al., 1998) (Fig. 1A). 
Although prion diseases are defined based on the presence of a disease-associated protease-
resistant PrP that has been proven to retain infectivity, Gambetti et al. shifted this dogmatic 
definition. They reported on a series of individuals with dementia and spongiform 
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encephalopathy but with a PrP resistant to minimal amount of PK, thus designating this 
novel form of prion disease as variably protease-sensitive prionopathy (or VPSPr) (Gambetti et 
al., 2008). Interestingly, in these cases the biochemical pattern of PrP is variable, as it 
contains both C-terminal fragments and intermediate fragments with molecular masses 
ranging from 20kDa to 7kDa (Zou et al., 2010) (Fig. 1A).  
Over the last few years, the PrPSc biochemical types described in animal prion disorders 
have consistently increased, following the systematic testing of over 30-month-old cattle, 
carried out by several European countries in 2001. The diagnostic test relied on the detection 
of protease-resistant PrP by Western blot in the animals’ brain tissue. This preventive 
measure allowed to detect all BSE-affected cattle, but also to recognize two additional BSE-
associated PrPSc types, distinguished from classical BSE (C-BSE) for the different 
electrophoretic migration and pattern of PrP glycosylation. According to the higher and 
lower electrophoretic migration of the unglycosylated fragment of PrPSc compared to C-BSE, 
these ”atypical” BSE forms were named H-type and L-type BSE, respectively (Biacabe et al., 
2004, Casalone et al., 2004) (Fig. 1B). 
The wide scale screening testing for prions on small ruminants resulted in similar findings, 
since additional PrPSc types were also found in scrapie. In particular, beside the classical 
scrapie strain, other atypical forms — originally named Nor 98 — have been reported; these 
are characterized by small intermediate truncated fragments of PrP associated to PrP27-30 
(Benestad et al., 2003, Benestad et al., 2008) (Fig. 1C).  
 
Fig. 1. PrPSc fragment patterns in human and animal prion disorders. Gel pattern of PrPSc in 
human forms (A), in BSE affected cattle (B), and in scrapie in sheep (C). Strains of TSE are 
defined in part by biochemical properties of PrPSc (glycosylation and size), pattern of PrPSc 
deposition in brain, and average age of disease onset. 
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3.3 Correlation between biochemical phenotypes of PrP
Sc
, disease-phenotypes and 
prion strain biological properties 
Several studies indicate that distinct PrPSc patterns represent the molecular signature of 
prion and have relevant biological implications including neuropathological phenotype and 
transmissibility. For instance, the occurrence of spongiform changes or amyloid deposits are 
strictly dependent on PrPSc species in brain tissue (Table 1). 
 
sCJD, fCJD, 
iCJD 
vCJD FFI 
GSS 
Classic         P102L 
VPSPr 
Clinical 
Phenotype 
Subacute 
dementing illness 
with visual, 
cerebellar and/or 
extrapyramidal 
signs, myoclonus 
Psychiatric 
features, 
painful 
distal 
sensations, 
cerebellar 
signs 
Sleep 
disruption, 
dysautonomia, 
motor 
abnormalities 
Slow 
progressive 
dementia and 
ataxia, 
pyramidal and 
extrapyramidal 
signs 
As sCJD 
or classic 
GSS 
 
Cognitive 
decline, 
mood or 
behavioural 
changes 
 
Disease 
Duration 
Weeks, months, 
less than two 
years 
Months 
or years 
15 
months 
(6-42) 
5-6 years 
36 
months 
(3-72) 
20 
months 
(10-60) 
Pathological 
Phenotype 
SD, astrogliosis, 
neuronal loss, 
amyloid plaques 
SD, 
astrogliosis, 
neuronal 
loss, 
florid 
amyloid 
plaques 
SD, 
astrogliosis, 
neuronal loss, 
mainly 
thalamic 
Widespread 
amyloid 
deposits, 
neuronal loss, 
astrogliosis, 
NFTs 
SD, 
astrogliosis 
or 
as classic 
GSS 
 
SD, 
minimal 
astrogliosis 
 
Pattern of PrP 
Deposition 
Synaptic/punctate, 
and/or amyloid 
plaques 
Synaptic/ 
punctate, 
florid 
plaques 
Fine 
punctuate 
staining 
Multi-centric 
amyloid 
plaques 
As sCJD 
or in 
classic 
GSS 
 
Intense 
staining, 
plaque- and 
dot-like 
 
PrPSc 
Biochemical 
Phenotype 
Type 1 
Type 2A 
CTF12-14 
Type 2B 
CTF12-14 
Type 2B-like 
CTF12-14 
PrP8 and 
11kDa 
IFs 
PrP27-30 
and 
PrP8 
CTFs 
IFs 
Transmissible Yes Yes Yes No Yes/No Pending 
Legend: iCJD: iatrogenic CJD; SD: spongiform degeneration; NFTs: neurofibrillary tangles; CTFs: C-
terminal fragments; IFs: intermediate fragments; PsPr: protease-sensitive PrP;  
Table 1. Disease characteristics of human prion disorders 
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However, this assumption is not fulfilled in GSS, since subjects carrying mutations, which 
segregate with GSS, except P102L, show a different disease phenotype, lacking PrP27-30 
(Ghetti et al., 2003). As expected, spongiform changes are not observed and the intermediate 
fragments promote a PrP amyloidogenesis process widespread to all brain tissue. 
Experimental studies in vitro showed the high propensity of these peptides to form amyloid 
aggregates (Salmona et al., 2003). Further, GSS does not propagate as a spongiform 
encephalopathy. In other words, unlike other prion diseases, GSS shares the disease 
characteristics of several other non-transmissible neurodegenerative disorders (Fig. 2). 
A first link between PrP pattern and pathological phenotype involves PrP27-30 and the 
detection of spongiform degeneration. In general all prion disorders associated with PrP27-
30, either in humans or in animals, are characterized by spongiform degeneration and 
astrogliosis. Further, the presence of PrP27-30 is related to transmissibility in susceptible 
recipients (Fig. 2). 
In contrast, in P102L mutation spongiform changes and diffuse multicentre amyloid plaques 
are observed, sharing disease characteristics of both CJD and GSS. These findings correlate 
to the presence of both PrP27-30 and PrP8 (Wadsworth et al., 2006), and only P102L cases 
with PrP27-30 transmitted the disease, whereas others did not. In particular, a spongiform 
encephalopathy was observed only in transgenic mice challenged with P102L human cases 
showing spongiform degeneration and PrP27-30 (Piccardo et al., 2007). 
 
Fig. 2. Correlative analysis between PrPSc fragments and pathological phenotype. 
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In sCJD, the biochemical phenotype of PrPSc comprises both PrP27-30 and CTFs, resulting in 
a spongiform encephalopathy and different patterns of PrP deposition.  
Conversely, in GSS, where PrP deposits consist of an intermediate fragment (PrP8), which 
lacks post-translational modifications including GPI anchor, the pathological phenotype is 
characterized by PrP amyloid multicentric plaques (arrows). 
VPSPr-affected subjects have a weakly PK-resistant PrP and neuropathologically they show 
the distinct feature of a spongiform encephalopathy. As mentioned above, both PrP C-
terminal fragments ― indicating that most of them are GPI-anchored ― consist mainly of 
those fragments forming the PrP pattern. Since IFs do not generate spongiform changes, 
these findings indicate that GPI-anchored PrP molecules might be associated with 
spongiform degeneration. As known from transgenic GPI anchorless mice, GPI anchorless 
PrP is able to replicate inducing an amyloidotic disease but not a spongiform 
encephalopathy (Chesebro et al., 2005). 
3.4 The biological properties of prion strains are enciphered in the biochemical 
pattern of PrP
Sc
: A lesson from two-dimensional analysis 
In sCJD, a sextet of subtypes was recognized, characterized by disease phenotypic 
heterogeneity, which results from the combination of two PrPSc types and the 
polymorphism M/V at codon 129 (Parchi et al., 1999). 
A decade ago we performed a 2D analysis ― which separates proteins by molecular weight 
and isoelectric point ― aimed at introducing a technique to better define the biochemical 
phenotype of PrPSc, beyond the conventional patterns obtained by SDS-PAGE (Zanusso et 
al., 2002). In particular, we argued whether additional PrP conformers might be observed 
within a given PrP27-30 band. In all sCJD cases associated with type 1 PrPSc, regardless of 
the polymorphism at codon 129, the 2D pattern of PrP27-30 and C-terminal fragments 
(CTFs) is identical (Fig. 3A). Conversely, we showed that type 2 PrPSc separated as two 
distinct patterns, one in MM2 cortical (MM2C) and the other in MV2 and VV2, which 
correlated with distinct pathological phenotypes. In particular, MM2 is characterized by a 
severe SD in the cerebral cortex with a relative spare of the cerebellum and a coarse pattern 
of PrP deposition, while in MV2 and VV2 the distribution of lesions is more diffuse, mostly 
concentrated in the cerebellum, with abundant amyloid plaques (Zanusso et al., 2004) (Fig. 
3B and 3C). 
PrP27-30 core fragment is depicted in black. The different spots composing PrP27-30 
represent the N-terminally truncated fragments. The 16-17-kDa and the 12-14 kDa truncated 
fragments are seen in sCJD with type 1, and correlate to a synaptic PrP staining seen in the 
frontal cortex and cerebellum. MM2C and MV2/VV2 subtypes show distinct PrP 27-30 
patterns and CTFs. In MM2C, CTFs are composed of 12-14 kDa species, while in MV2/VV2 
these consist of 16-17kDa fragments. These biochemical patterns correlate to distinct 
pathological phenotypes. 
These results were subsequently confirmed by transmission studies. In transgenic mice 
targeting and expressing different forms of PRNP (MM, MV, VV), MM1 and MV1 isolates 
showed similar biological properties, while the strain associated with an MV2 patient could 
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not be distinguished from the VV2 strain, and MM2 isolate transmitted poorly (Bishop et al., 
2010). In the bank vole, MM1 and MV1 CJD also behaved as similar agents, and differed 
from MM2 CJD. MV2 and VV2 did not transmit (Nonno et al., 2006). 
 
Fig. 3. Schematic diagram of PK-resistant C-terminal PrP core fragments in sCJD subtypes.  
3.4.1 The biochemical link between animal and human prion forms is enciphered in 
PrP
Sc
 
We firstly proposed a parallel between sCJD in humans and BSE in cattle, by showing that 
MV2 sCJD subtype shared molecular similarities with cattle affected with bovine 
amyloidotic spongiform encephalopathy (BASE) including the pathological phenotype 
(Casalone et al., 2004, Brown et al., 2006). As in humans, two presumably sporadic forms 
of BSE are observed in cattle in addition to typical/classical BSE. Moreover, the apparent 
molecular weight of the unglycosylated band of bovine amyloidotic spongiform 
encephalopathy is identical to that of type 2A, while H-type BSE corresponds to type 1 
PrPSc (Fig. 4). Of course, the link between C-BSE and vCJD had been largely 
demonstrated. 
Wemheuer et al. proposed a correlation between classical and atypical/Nor98 scrapie in 
sheep and sCJD, showing that the two scrapie types share a number of striking similarities 
with human PrPSc types in sCJD (Wemheuer et al., 2009) (Fig. 4). 
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Fig. 4. Correlative analysis of PrPSc biochemical phenotype in different BSE, CJD and scrapie 
isolates. Arrows link human and animal forms. 
4. Conclusion 
The existence of different PrPSc types might be a common denominator of prion diseases in 
humans and animals and it might suggest the existence of different conformers within a 
given prion disorders. Further, although the biochemical approach is important for large-
scale studies, it should be clear that for strain recognition and comparative analysis 
purposes, PrPSc biochemical similarity is only apparent evidence, and it does not reflect the 
biological properties of a given strain. These are revealed only after transmission.  
In addition, the demonstration that synthetic prion strains can be made in the laboratory has 
ushered in a large set of experimental investigations that may help deciphering the 
structural determinants linked to different PrPSc types. 
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